$DRMAW News
Last published 3y ago
- 3y agoDRMADRMAWDermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial ResultsACCESS Newswire- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2023 -- DMT410
- 4y agoDRMADRMAWDermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announce
- 4y agoDRMADRMAWDermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today anno
- 4y agoDRMADRMAWDermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateACCESS Newswire- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - - Topline results from DMT410 POC study in multiple ae
- 5y agoDRMADRMAWDermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual MeetingACCESS NewswireThe presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin for multiple aesthetic skin conditions SAN DIEGO, CA
- 5y agoDRMADRMAWDermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial OfficerACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the development of novel dermatology therapies, today announced t
- 5y agoDRMADRMAWDermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public OfferingACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW))), a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical p
- 5y agoDRMADRMAWDermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public OfferingACCESS NewswireSAN DIEGO, CA / ACCESSWIRE / August 12, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceuti